New Chicago ARC Innovation Center
Chicago ARC Innovation Center is envisioned to connect the best science, talent, and technology to achieve health equity through a collaborative innovation platform
New Sheba Study Indicates that COVID-19 Infection Rates Are Significantly Reduced After a Single Dose of the Pfizer-BioNTech Vaccine
An 85% reduction in symptomatic COVID-19 infections among the recipients of the first dose of the Pfizer-BioNTech vaccine is indicated by new Sheba study. Learn more:
New Respiratory Support System Offers an Alternative to Invasive Mechanical Ventilation
Innovative Blood Oxygenation System Could Help Treat COVID-19 Patients Without Requiring Anesthesia. Click Here to Learn More:
VR Technology Offered to Cancer Patients in an Effort to Alleviate Pain and Anxiety
Recent Studies Indicate that the Use of VR Technology, Now Available at Sheba Medical Center, Can Help Alleviate Pain and Anxiety. Click Here to Learn More.
Agminated Benign Vascular Tumor Successfully Treated with Trametinib
Novel treatment successfully used to treat a vascular tumor at Sheba Medical Center
New Mini Ultrasound Device Allows Remote Monitoring of Pregnant Women in COVID-19 Wards
Innovative Mini Ultrasound Device Allows Remote Monitoring of Pregnant Women Quarantined Due to COVID-19 at Sheba Medical Center
Hypertension Treatment – An Innovative Technique at Sheba Medical Center
Recent studies indicate that a new hypertension treatment, now available at Sheba, may help achieve a sustained reduction in blood pressure, independent of patient medication adherence.
Sheba Medical Center becomes the first Israeli medical institution to operate in the UAE
For the first time in UAE history, Israeli doctors are treating patients in a new Dubai clinic. Click here to learn more.
Innovative Heart Valve Correction Procedure at Sheba Medical Center
Novel tricuspid valve repair procedure performed at Sheba negates the need for a surgical incision.
Innovative hemato-oncological treatments
New studies indicate the high efficacy of novel immunotherapies, now available at Sheba, for patients with relapsed or refractory hematological malignancies.
